The 4th Edition of the India Biopharma Leaders Conclave, held at Le Meridien, Hyderabad, illuminated the burgeoning field of CAR T-cell therapy during a compelling panel discussion titled “Recent Advances & Future Prospective of CART T Cell Therapy.” Exploring the theme “New Horizons in Biopharma, Biosimilars, & Biologics”, the session of panel discussion guided the discourse through the latest developments and the forward-looking potential of CAR T cell therapies.
The session was led by Dr. AmitAwasthi, Senior Professor at the Translational Health Science & Technology Institute, who brought together an array of experts to discuss the latest advancements, hurdles, and future directions in this transformative area of cancer treatment.
The panel comprised Dr. Kishore J.R. Kunapuli, Chief Scientific Officer at Pulse Pharmaceuticals Pvt. Ltd., Dr. Akhil Kumar, Chief Medical Officer at Aurigene Oncology, and Dr. BajarangKumbhar, Assistant Professor at the Department of Biological Sciences, NMIMS. Each panelist brought unique insights from their extensive work in developing and deploying CAR T-cell therapies.
Rapid Advancements & Regulatory Challenges
The session opened with Dr. Awasthi highlighting the rapid pace of development in the field, particularly noting that every significant global update seems to be accompanied by new regulatory challenges. He pointed out the significance of India’s first CD19 CAR T-cell product developed in collaboration with Tata Memorial, emphasizing the need for expanded manufacturing capabilities across India to meet the high demand due to the large patient base.
Dr. BajarangKumbhar shared his direct involvement with the project, detailing the structural components of CAR T-cells, including the ectodomain, transmembrane domain, and endodomain. His explanation shed light on the complexities of designing CAR T-cells that can effectively target cancer cells without causing adverse effects like cytokine release syndrome.
Industrial & Academic Synergy
A recurring theme throughout the discussion was the critical importance of collaboration between academia and industry. Dr. Kishore J.R. Kunapuli discussed the innovative approaches being explored to enhance the efficacy of CAR T-cell therapies, including modifications to the cellular design to improve antigen recognition independent of the major histocompatibility complex (MHC). This innovation could potentially lead to broader applications of CAR T-cell therapy beyond the current limitations posed by MHC dependency.
Dr. Akhil Kumar addressed the logistical and financial challenges of bringing CAR T-cell products to market. He highlighted the exceptional cost of CAR T-cell therapy, which remains a significant barrier to accessibility. Dr. Kumar advocated for the development of a robust ecosystem within India to reduce costs, involving local production of critical components like viral vectors and cytokines.
Looking to the Future
The future of CAR T-cell therapy in India looks promising yet demanding, with the need for significant advancements in both the scientific and regulatory arenas. The panelists discussed the potential for next-generation CAR T-cell therapies that incorporate novel domains to enhance their persistence and efficacy. They also touched on the potential integration of technologies like CRISPR for more precise genetic editing, improving the safety profile of these therapies.
As the discussion concluded, the need for a supportive regulatory framework that can keep pace with rapid technological advances was underscored as essential for the continued growth and success of CAR T-cell therapies in India. The panelists called for more government-backed GMP facilities and regulatory reforms to streamline the approval processes for new therapies.
The panel provided a comprehensive overview of the current state and exciting future of CAR T-cell therapy. It highlighted the innovative spirit within India’s biopharma sector, poised to take a leading role on the global stage by addressing the unique challenges of developing and deploying cutting-edge therapies in a highly regulated and technically complex field.
– Raja Aditya
Read more about India Biopharma Leaders Conclave
